Evidence map›Paper›PMID 24465475›Full record

ArticlePloS one2014

The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal.

Andrew S J Marshall, Charlotte I S Barker, Anoop S Pulickal, Elizabeth Kibwana, Samir C Gautam, Elizabeth A Clutterbuck, Stephen M Thorson, Shrijana Shrestha, Neelam Adhikari, Andrew J Pollard and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Andrew S J MarshallOxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Charlotte I S BarkerOxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Anoop S PulickalOxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Elizabeth KibwanaOxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Samir C GautamPatan Hospital, Kathmandu, Nepal.
Elizabeth A ClutterbuckOxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Stephen M ThorsonPatan Hospital, Kathmandu, Nepal.
Shrijana ShresthaPatan Hospital, Kathmandu, Nepal.
Neelam AdhikariPatan Hospital, Kathmandu, Nepal.
Andrew J PollardOxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Dominic F KellyOxford Vaccine Group, Oxford University, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
Patan Hospital · NPUniversity of Oxford · GBOxford BioMedica (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haemophilus influenzae type b (Hib) is now recognized as an important pathogen in Asia. To evaluate disease susceptibility, and as a marker of Hib transmission before routine immunization was introduced in Kathmandu, 71 participants aged 7 months-77 years were recruited and 15 cord blood samples were collected for analysis of anti-polyribosylribitol phosphate antibody levels by enzyme-linked immunosorbent assay. Only 20% of children under 5 years old had levels considered protective (>0.15 µg/ml), rising to 83% of 15-54 year-olds. Prior to introduction of Hib vaccine in Kathmandu, the majority of young children were susceptible to disease.

Indexed as

AdolescentAdultAgedAntibodies, BacterialBacterial CapsulesChildChild, PreschoolEnzyme-Linked Immunosorbent AssayHaemophilus InfectionsHaemophilus influenzae type bHaemophilus VaccinesHost-Pathogen InteractionsHumansImmunization ProgramsInfantMiddle AgedAntibodies, BacterialHaemophilus influenzae type b polysaccharide vaccineHaemophilus Vaccinespolyribitol phosphatePolysaccharidesPolysaccharides, Bacterial

Identifiers

PMID24465475
PMCPMC3898912
OpenAlexW2042950306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.